Company’s New Groundbreaking Preclinical Data in NSCLC Models Provides Further Validation for SIL204's Innovative Delivery ...

Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations ...

Silexion Therapeutics reports positive preclinical results for SIL204 in lung cancer, advancing dual-route administration and preparing for upcoming clinical trials.

Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the ...

Silexion Therapeutics Corp (NASDAQ:SLXN) announced Tuesday that it received a favorable decision from a Nasdaq hearings panel, allowing the company to remain listed on the exchange, subject to certain ...

Silexion Therapeutics Corp (NASDAQ:SLXN) announced Tuesday that it received a favorable decision from a Nasdaq hearings panel, allowing the company to remain listed on the exchange, subject to ...

Get the latest Silexion Therapeutics Corp (SLXNW) stock news and headlines to help you in your trading and investment decisions.

Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination The combined company’s shares and warrants are expected to begin trading on Nasdaq under the ...

Review the current Silexion Therapeutics Corp (SLXN:XNAS) dividend yield and history to decide if SLXN is the best investment for you.

A high-level overview of Silexion Therapeutics Corp Wt Exp (SLXNW) stock. View (SLXNW) real-time stock price, chart, news, analysis, analyst reviews and more.